Literature DB >> 3631160

Another look at the second-assessment procedure for ovarian epithelial carcinoma.

D G Gallup, O E Talledo, M R Dudzinski, K W Brown.   

Abstract

Over a 10-year period, 65 of 196 patients (33%) with ovarian epithelial malignancy, previously treated with chemotherapy, had a second-look operation if the disease was clinically absent. All procedures were done by one of three gynecologic oncologists, and 48% of the patients had a positive second-look procedure. Of patients with original stage I, II disease, 25% had a positive second-look operation, contrasting with 61% of patients with stage III, IV. Significant perioperative morbidity occurred: one patient had intraoperative vascular collapse; 15% had prolonged ileus; 17% had small bowel resections at the time of the second-look operation or in the postoperative period. Of all patients with negative second-look operations, 24% have had recurrent disease from 5 to 23 months after the procedure. These recurrences were in the liver or distant sites in 63% of the patients. Second-look operations, if still indicated by negative noninvasive techniques, should be performed in tertiary care centers under study situations in a standard fashion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3631160     DOI: 10.1016/s0002-9378(87)80012-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Imaging of ovarian cancer with radiolabelled monoclonal antibodies.

Authors:  D L van Kranenburg; M J van Kroonenburgh; J B Trimbos; G J Fleuren; E K Pauwels
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  Surgical second-look in epithelial ovarian cancer: high recurrence rate after negative results and lack of survival benefit limits its role in standard management.

Authors:  Salih Taşkın; Mete Güngör; Elif Aylin Taşkın; Fırat Ortaç
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

Review 3.  The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

Authors:  A E Selman; L J Copeland
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.